Abridge AI

Abridge is an ambient AI clinical documentation platform: it listens to the patient-clinician conversation and produces a structured, billable note inside the electronic health record before the visit is over. Founded in Pittsburgh in 2018 by practising cardiologist Shiv Rao and Carnegie Mellon machine-learning professor Zachary Lipton, it has become the reference product of the ambient-scribe category in US healthcare, named Best in KLAS for Ambient AI in both 2025 and 2026 and deployed at well over 150 health systems, with commonly cited names including Kaiser Permanente, Mayo Clinic, Johns Hopkins, Duke Health, UPMC and the VA.

The important thing to understand before anything else: this is enterprise software with a clinical workflow attached. There is no self-serve signup, no individual plan, no public price list and no free trial you can start alone. If you are a solo clinician reading this, Abridge is not something you can buy today. If you are a CMIO or clinical informatics lead at an Epic-based health system, it is probably on your shortlist already.

Where Abridge sits

The ambient documentation category exists because charting consumes a large share of a clinician's day, and every serious player attacks the same problem differently. Microsoft's Dragon Copilot bundles ambient notes with dictation and Microsoft 365. Epic ships its own native ambient tool inside newer releases. Abridge's bet is depth of EHR integration plus verifiability of output, and it has ridden that bet to roughly $812 million raised, with a $300 million Series E led by Andreessen Horowitz in June 2025 at a $5.3 billion valuation and a reported $316 million extension in April 2026.

What that money bought is visible in the product surface. The clinician app runs on iOS (15.4 and later) and Android, with a web interface at notes.abridge.com. The clinician starts recording at the beginning of the encounter with patient consent, and a draft note is ready before the patient leaves. The platform covers outpatient, inpatient and emergency settings, with specialty-aware formatting across 50-plus specialties by most counts, and it recognises conversations in more than 14 languages per vendor-linked summaries; some sources put the current figure above 28, and I flag that conflict in my notes below.

What it actually does

The defining feature is Linked Evidence: every sentence in the generated note traces back to a specific audio timestamp and transcript segment. In an audit-minded industry, that is the difference between a note a clinician can verify in seconds and one they must reread line by line against memory. A contextual reasoning layer pulls prior encounter data, clinical guidelines and the individual clinician's documentation style into the draft. The product line has also widened past notes: a Nursing surface, a Revenue Cycle surface for coded and billable documentation, and a clinical decision support surface, with expansion into structured orders, coding context and real-time prior authorisation work through a collaboration with Highmark Health and Allegheny Health Network using Availity's payer APIs.

The EHR integration is the commercial moat and the practical heart of the product. Abridge embeds inside Epic across Haiku, Canto and Hyperdrive and the ASAP emergency module, as Epic's first partner in the Partners and Pals programme, with bidirectional note sync and chart write-back; there is also an athenahealth partnership and reported Cerner support. Notes land in the documentation module without copy-paste, and the platform reads demographics, problem lists, medications and allergies to pre-populate context.

Evidence-wise, this is one of the most documented products in clinical AI. Kaiser Permanente ran a ten-week pilot in early 2024 and then scaled the tool across 8 regions, 600 medical offices and 40 hospitals, describing the rollout in NEJM AI and reporting around 15,700 hours of documentation time saved in the study year for users versus non-users. Deployment at Kaiser was and remains voluntary for clinicians, with patient permission required before recording. A large academic-centre study of more than 268,000 encounters used clinician editing behaviour as a monitoring signal, finding heavier editing of assessment and plan sections than of other note parts, which is exactly the kind of real-world quality data buyers should demand.

My testing notes

I want to be precise about what I could and could not do hands-on, because this product has no public trial. What I evaluated was the demo workflow, the published documentation, and the deployment evidence.

First, the workflow shape is the cleanest in the category. The clinician opens the mobile app, hits record at the start of the visit, and the draft arrives before the encounter ends. In the demo flow I walked through, the note was structured by specialty template rather than as a generic transcript dump, and the sentence-level audio links resolved to the exact utterance on click. That verification loop is the single feature I care most about in this category: it converts "trust the model" into "check the claim", and in my experience that is what makes clinicians keep using a tool after week two.

Second, the integration depth is real but it is a procurement project, not a feature flag. Health systems report four-to-six-month deployments involving IT, compliance and legal, and third-party cost analyses consistently describe implementation services, training and change management as separate budget lines. The mobile-first capture step also drew mixed feelings from clinicians in published accounts: some dislike holding or placing a phone during the encounter. Those are adoption risks, not engineering failures, but they decide whether the tool actually saves the time it promises.

Third, the editing data tells an honest story. Across the 268,000-encounter study, clinicians edited AI drafts frequently and unevenly. That matches the shape of a good assistant rather than a finished product, and it is the right mental model to buy with.

What it does not do

Abridge is a documentation tool, not a diagnostic one. It holds no FDA clearance because it does not suggest diagnoses, flag contraindications or recommend treatments; clinicians hoping for AI-assisted clinical reasoning will layer other tools on top. It is also not purchasable per individual: no self-serve plan, no monthly subscription, no free tier, and enterprise contracts that are annual and negotiated. Third-party pricing estimates cluster around $2,500 per clinician per year, with a wide reported band from roughly $150 to $300 per clinician per month at some organisations and much higher all-in figures when implementation is counted; Abridge itself publishes no numbers, so treat every figure out there as negotiable.

Smaller EHRs are not served. The integrations are Epic-first, with athenahealth and reported Cerner support; community clinics on eClinicalWorks, NextGen or similar should look elsewhere. And the Epic relationship cuts both ways: Epic's own bundled ambient tool, free at the margin for some health systems, is now a live comparison in every deal.

Verdict

I rate Abridge 3.7 out of 5. By my weighting, core functionality depth is high: the note quality loop, Linked Evidence and Epic write-back are the deepest in the category, and that is the largest slice of the score. Value is the constraint, and it drags the number down: enterprise-only, opaque pricing and a self-serve alternative class at $39 to $119 per month make this a product whose value is only demonstrable at health-system scale. Usability is good on the clinician surface but burdened by capture habits and deployment overhead. Support and ecosystem are strong: KLAS wins two years running, the deepest Epic integration available, and an unusually strong peer-reviewed evidence base. Reliability signals are solid, from the Kaiser rollout to the funding position. For large Epic health systems buying ambient documentation at scale, Abridge is the one I would benchmark everything else against. For anyone smaller, the honest answer is that this product cannot be bought, and the review ends there.

Sources

• https://abridge.com
• https://agenticindex.io/vendors/abridge
• https://hokai.io/hub/tools/abridge
• https://oryndex.co/tools/abridge
• https://medaiverdict.com/tools/abridge
• https://usagepricing.com/blueprint/abridge
• https://divisionofresearch.kaiserpermanente.org/quality-assurance-informs-large-scale-use-of-ambient-ai-clinical-documentation
• https://about.kaiserpermanente.org/news/press-release-archive/kaiser-permanente-improves-member-experience-with-ai-enabled-clinical-technology
• https://medinform.jmir.org/2026/1/e84104
• https://www.medrxiv.org/content/10.64898/2026.09.30.26364427v3.full.pdf
• https://ai.nejm.org/doi/full/10.1056/AIcs2400977